@vfsglobalcare I have been trying for over a week now. Due to lack of transparency with the process I doubt I can beat a bot or an agent to this. There are multiple social media posts and discussions that have raised this concern, surely there is a problem that needs addressed.@EU_Commission
In a study published in NEJM involving more than 1700 patients with cancer-related VTE, reduced-dose apixaban (2.5 mg twice daily) resulted in similar 12-month VTE recurrence rates compared with full-dose (5 mg twice daily) apixaban (2.1 versus 2.8 per cent). However, fewer patients receiving reduced-dose apixaban experienced clinically significant bleeding compared with patients receiving full-dose apixaban (12.1 per cent versus 15.6 per cent).
@NEJM
While evidence showing questionable benefits of mannitol prior to vessel clamping exists.
We published our pragmatic RCT addressing a few knowledge gaps in use of mannitol for partial nephrectomy with a robust study design to eliminate any contamination of effect
๐จ Breaking results ๐จ @PrimeMRI study presented at #EAU24@Uroweb. This ๐ multicentre trial (n=555, 22 sites) showed that biparametric MRI without contrast is non-inferior 2 multiparametric MRI & should be the new standard for prostate cancer diagnosis if image quality is good
The new EAU Guidelines App is here! This new interactive resource will help you optimise your #EAUGuidelines searches, keep your favorite tools on hand and get you diagnostic answers quickly and easily. Download it now!
๐ฒhttps://t.co/gHMwej4HDp
1/ Results from #COSMIC-313 are out @NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by @CharlesSwanton@AndresC27622123#ESMO22
Thread ๐งต==>
https://t.co/cSx457HpLM
We are excited to announce that https://t.co/bkf4xOOX4m v2 is released! We are so thankful to all the many authors in the #PedUro community who contributed to this free resource.